Vancomycin Exposure and Genetic Variation
In this 36-patient cohort, AUC24/MIC estimation and a single genetic variant were associated with differences in measured vancomycin exposure, but the study does not establish a causal pharmacogenetic dosing approach.
> Research explainer: This briefing examines verified primary research published 72 days before the briefing date. It is not a same-day research update and does not provide medical advice.
Evidence
The study followed 36 adults at one center who received intravenous vancomycin for at least 72 hours. Fourteen participants, or 38.9%, developed vancomycin-associated acute kidney injury (VA-AKI). The cohort was designed to compare trough-concentration monitoring with two ways of estimating the 24-hour area-under-the-curve to minimum inhibitory concentration ratio (AUC24/MIC): pharmacokinetic equations and a Bayesian method. It also evaluated the rs2789047 variant in relation to clinical and pharmacokinetic parameters. [pmid:42310132]
Trough concentration and AUC24/MIC moved together strongly in this cohort, with correlations of 0.84–0.87. Yet correlation did not translate into interchangeable therapeutic classifications. Agreement between trough-based monitoring and pharmacokinetic equation-based AUC24/MIC classification was 63.9%; agreement between trough-based monitoring and Bayesian AUC24/MIC classification was 66.7%. By comparison, the two AUC24/MIC methods agreed in 86.1% of classifications. [pmid:42310132]
Higher trough concentrations and higher AUC24/MIC values were significantly associated with VA-AKI in the reported analyses (p<0.001). The report also found that participants carrying the rs2789047 A allele had higher trough concentrations and reduced elimination rates. These are observed associations within the enrolled cohort, not evidence that the allele itself causes altered vancomycin handling or kidney injury. [pmid:42310132]
Analysis — Monitoring Concordance and Genetic Exposure
The central genetics-and-genomics signal is modest but specific: rs2789047 A-allele carriage tracked with two pharmacokinetic features that influence measured vancomycin exposure—higher trough concentrations and reduced elimination rates. [pmid:42310132] The finding sits alongside a monitoring result with practical interpretive importance: measures can be highly correlated while still assigning a substantial share of individuals to different therapeutic categories. [pmid:42310132] Here, trough-based classification agreed with either AUC24/MIC approach only about two-thirds of the time, whereas the two AUC24/MIC approaches agreed more often. [pmid:42310132] That pattern supports treating a trough value and an estimated exposure metric as related but non-identical representations of drug exposure in this study. [pmid:42310132] It does not show that genotyping rs2789047 improves outcomes, identifies an optimal dose, or can replace concentration-based monitoring. The appropriate research interpretation is that genetic variation may contribute to interindividual exposure variability and merits testing in larger, diverse cohorts with outcome-focused designs. [pmid:42310132]
Limitations
This was a prospective study, which supports systematic data collection, but it was conducted at a single center and enrolled only 36 adults. A result based on this sample may not extend to other hospitals, ancestry groups, ages, infection settings, dosing practices, or patients with different renal function. Eligibility required creatinine clearance of at least 30 mL/min, and the study excluded several groups, including people requiring renal replacement therapy within the first 72 hours and those receiving overlapping anti-MRSA therapy for at least 24 hours. [pmid:42310132]
The genetic analysis concerned one variant, rs2789047, rather than a comprehensive pharmacogenetic model. The supplied evidence reports associations between A-allele carriage and exposure-related parameters; it does not demonstrate mechanism, causality, independent replication, or clinical utility. Similarly, the association of higher exposure measures with VA-AKI does not isolate vancomycin exposure from all possible contributors to kidney injury in this cohort. The study recorded concomitant nephrotoxic agents, but the supplied findings do not establish a causal attribution for any individual factor. [pmid:42310132]
Finally, monitoring-method concordance is a classification comparison, not an outcomes trial. The higher agreement between the two AUC24/MIC approaches does not by itself prove either method is superior for every patient or setting. These results are best read as a bounded research observation: in this defined cohort, exposure estimates, therapeutic categories, kidney-injury associations, and one genetic marker did not map perfectly onto one another. [pmid:42310132]